Resveratrol and its analogs as antitumoral agents for breast cancer treatment

Mini-Reviews in Medicinal Chemistry

Volumn 16, Issue 9, 2016, Pages 699-709

  Chimento, Adele ^a   Sirianni, Rosa ^a   Saturnino, Carmela ^b   Caruso, Anna ^a   Sinicropi, Maria Stefania ^a   Pezzi, Vincenzo ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

Analogs; Antitumoral Agents; Breast Cancer; Cell Growth Inhibition; RSV; RSV Bioaccessibility

Indexed keywords

1,4 BIS (4 BROMOPHENYL) 3 CHLOROAZETIDIN 2 ONE; 2 (3,4 DIMETHOXYPHENYL) 3 (4 HYDROXYPHENYL) THIAZOLIDIN 4 ONE; 2 (3,4,5 TRIMETHOXYPHENYL) 3 P TOLYLTHIAZOLIDIN 4 ONE; 2 (4 CHLOROPHENYL) 3 (4 HYDROXYPHENYL)THIAZOLIDIN 4 ONE; 2 (NAPHTHALEN 1 YL) 3 P TOLYLTHIAZOLIDIN 4 ONE; 2,3 DIPHENYLTHIAZOLIDIN 4 ONE; 2,3 THIAZOLIDIN 4 ONE; 3 CHLORO 4 (4 CHLOROPHENYL) 1 (4 IODOPHENYL)AZETIDIN 2 ONE; 4 (6 HYDROXY 2 NAPHTHYL) 1,3 BENZENEDIOL; PTEROSTILBENE; PTEROSTILBENE ISOTHIOCYANATE CONJUGATE; RESVERATROL; ROSIGLITAZONE; TRANS 3,3,4,4,5,5 HEXAHYDROXYSTILBENE; TRANS 3,4,5,4 TETRAMETHOXYSTILBENE; TRANS 3,5,3,4,5 PENTAMETHOXYSTILBENE; TRANS 3,5,4 TRIACETYL STILBENE; TRANS 3,5,4 TRIMETHOXYSTILBENE; TRANS 4,4 DIHYDROXY STILBENE; TRANS RESVERATROL 3 O D GLUCURONIDE; TRANS RESVERATROL 3 SULPHATE; TRANS RESVERATROL 4 O D GLUCURONIDE; TROGLITAZONE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; STILBENE DERIVATIVE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOAVAILABILITY; BREAST CANCER; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMICAL MODIFICATION; GROWTH INHIBITION; HUMAN; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; FEMALE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; STILBENES;

EID: 84964290937     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557516666160321113255     Document Type: Article

References (121)

1. Wong, R.S. Apoptosis in cancer: from pathogenesis to treatment. J. Exper. Clin. Cancer Res.: CR, 2011, 30, 87.
2. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D., Global cancer statistics. CA Cancer J. clin., 2011, 61(2), 69-90.
3. Gandini, S.; Merzenich, H.; Robertson, C.; Boyle, P. Meta-analysis of studies on breast cancer risk and diet: the role of fruit and vegetable consumption and the intake of associated micronutrients. Eur. J. Cancer, 2000, 36(5), 636-646.
4. Lee, S.A.; Shu, X.O.; Li, H.; Yang, G.; Cai, H.; Wen, W.; Ji, B.T.; Gao, J.; Gao, Y.T.; Zheng, W. Adolescent and adult soy food intake and breast cancer risk: results from the Shanghai Women's Health Study. Am. J. Clin. Nutr., 2009, 89(6), 1920-1926.
5. Wu, A.H.; Ziegler, R.G.; Nomura, A.M.; West, D.W.; Kolonel, L.N.; Horn-Ross, P.L.; Hoover, R.N.; Pike, M.C. Soy intake and risk of breast cancer in Asians and Asian Americans. Am. J. clin. Nutr., 1998, 68(6 Suppl), 1437S-1443S.
6. Mense, S.M.; Hei, T.K.; Ganju, R.K.; Bhat, H.K. Phytoestrogens and breast cancer prevention: possible mechanisms of action. Environ. Health Perspect., 2008, 116(4), 426-433.
7. Mueller, S.O. Overview of in vitro tools to assess the estrogenic and antiestrogenic activity of phytoestrogens. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2002, 777(1-2), 155-165.
8. Duffy, C.; Perez, K.; Partridge, A. Implications of phytoestrogen intake for breast cancer. CA cancer J. clinic., 2007, 57(5), 260-277.
9. Nobili, S.; Lippi, D.; Witort, E.; Donnini, M.; Bausi, L.; Mini, E.; Capaccioli, S. Natural compounds for cancer treatment and prevention. Pharmacological Research: J. Ital. Pharmacol. Soc., 2009, 59(6), 365-378.
10. Nielsen, J. Combinatorial synthesis of natural products. Curr. Opin. Chem. Biol., 2002, 6(3), 297-305.
11. Mayr, L.M.; Bojanic, D. Novel trends in high-throughput screening. Curr. Opin. Pharmacol., 2009, 9(5), 580-588.
12. Harvey, A.L.; Cree, I.A. High-throughput screening of natural products for cancer therapy. Planta Med., 2010, 76(11), 1080-1086.
13. Iljin, K.; Ketola, K.; Vainio, P.; Halonen, P.; Kohonen, P.; Fey, V.; Grafstrom, R.C.; Perala, M.; Kallioniemi, O. High-throughput cellbased screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin. Cancer Res.: J. Am. Assoc. Cancer Res., 2009, 15(19), 6070-6078.
14. Gupta, P.B.; Onder, T.T.; Jiang, G.; Tao, K.; Kuperwasser, C.; Weinberg, R.A.; Lander, E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell, 2009, 138(4), 645-659.
15. Thierbach, R.; Steinberg, P. Automated soft agar assay for the high-throughput screening of anticancer compounds. Analyt. Biochem., 2009, 387(2), 318-320.
16. Dufau, I.; Lazzari, A.; Samson, A.; Pouny, I.; Ausseil, F. Optimization of a homogeneous assay for kinase inhibitors in plant extracts. Assay Drug Dev. Tech., 2008, 6(5), 673-682.
17. Hashimoto, J.; Watanabe, T.; Seki, T.; Karasawa, S.; Izumikawa, M.; Iemura, S.; Natsume, T.; Nomura, N.; Goshima, N.; Miyawaki, A.; Takagi, M.; Shin-Ya, K. Novel in vitro protein fragment complementation assay applicable to high-throughput screening in a 1536-well format. J. Biomol. Screen., 2009, 14(8), 970-979.
18. Xia, E.Q.; Deng, G.F.; Guo, Y.J.; Li, H.B. Biological activities of polyphenols from grapes. Intl J. Mol. Sci., 2010, 11(2), 622-646.
19. Raederstorff, D.; Kunz, I.; Schwager, J. Resveratrol, from experimental data to nutritional evidence: the emergence of a new food ingredient. Ann. New York Acad. Sci., 2013, 1290, 136-141.
20. Yu, W.; Fu, Y.C.; Wang, W. Cellular and molecular effects of resveratrol in health and disease. J. Cell. Biochem., 2012, 113(3), 752-759.
21. Fremont, L. Biological effects of resveratrol. Life Sci., 2000, 66(8), 663-673.
22. Pervaiz, S. Resveratrol: from grapevines to mammalian biology. FASEB J., 2003, 17(14), 1975-1985.
23. Kulkarni, S.S.; Canto, C. The molecular targets of Resveratrol. Biochim. Biophy. acta, 2014.
24. Athar, M.; Back, J.H.; Tang, X.; Kim, K.H.; Kopelovich, L.; Bickers, D.R.; Kim, A.L. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol., 2007, 224(3), 274-283.
25. Kulkarni, S.S.; Canto, C. The molecular targets of resveratrol. Biochim. Biophy. Acta, 2015, 1852(6), 1114-1123.
26. Carrizzo, A.; Forte, M.; Damato, A.; Trimarco, V.; Salzano, F.; Bartolo, M.; Maciag, A.; Puca, A.A.; Vecchione, C. Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem. Toxicol., 2013, 61, 215-226.
27. Frankel, E.N.; Waterhouse, A.L.; Kinsella, J.E. Inhibition of human LDL oxidation by resveratrol. Lancet, 1993, 341(8852), 1103-1104.
28. Belguendouz, L.; Fremont, L.; Linard, A. Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem. Pharmacol., 1997, 53(9), 1347-1355.
29. Fauconneau, B.; Waffo-Teguo, P.; Huguet, F.; Barrier, L.; Decendit, A.; Merillon, J.M. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sci., 1997, 61(21), 2103-2110.
30. Voloshyna, I.; Hussaini, S.M.; Reiss, A.B. Resveratrol in cholesterol metabolism and atherosclerosis. J. Med. Food, 2012, 15(9), 763-773.
31. Buryanovskyy, L.; Fu, Y.; Boyd, M.; Ma, Y.; Hsieh, T.C.; Wu, J.M.; Zhang, Z. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry, 2004, 43(36), 11417-11426.
32. Toliopoulos, I.K.; Simos, Y.V.; Oikonomidis, S.; Karkabounas, S.C. Resveratrol diminishes platelet aggregation and increases susceptibility of K562 tumor cells to natural killer cells. Ind. J. Biochem. Biophy., 2013, 50(1), 14-18.
33. Pace-Asciak, C.R.; Hahn, S.; Diamandis, E.P.; Soleas, G.; Goldberg, D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin. Chim. Acta Intl. J. Clin. Chem., 1995, 235(2), 207-219.
34. Yar, A.S.; Menevse, S.; Alp, E.; Helvacioglu, F.; Take, G. The effects of resveratrol on cyclooxygenase-1 and cyclooxygenase-2 mRNA and protein levels in diabetic rat kidneys. Mol. Biol. Rep., 2010, 37(5), 2323-2331.
35. Kutil, Z.; Temml, V.; Maghradze, D.; Pribylova, M.; Dvorakova, M.; Schuster, D.; Vanek, T.; Landa, P. Impact of wines and wine constituents on cyclooxygenase-1, cyclooxygenase-2, and 5-lipoxygenase catalytic activity. Mediat. Inflam., 2014, 2014, 178931.
36. Gordish, K.L.; Beierwaltes, W.H. Resveratrol induces acute endothelium-dependent renal vasodilation mediated through nitric oxide and reactive oxygen species scavenging. Am. J. physiol. Renal Physiol., 2014, 306(5), F542-550.
37. Shen, M.; Zhao, L.; Wu, R.X.; Yue, S.Q.; Pei, J.M. The vasorelaxing effect of resveratrol on abdominal aorta from rats and its underlying mechanisms. Vasc. Pharmacol., 2013, 58(1-2), 64-70.
38. Morselli, E.; Maiuri, M.C.; Markaki, M.; Megalou, E.; Pasparaki, A.; Palikaras, K.; Criollo, A.; Galluzzi, L.; Malik, S.A.; Vitale, I.; Michaud, M.; Madeo, F.; Tavernarakis, N.; Kroemer, G. Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell Death Dis., 2010, 1, e10.
39. Pallas, M.; Casadesus, G.; Smith, M.A.; Coto-Montes, A.; Pelegri, C.; Vilaplana, J.; Camins, A. Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection. Curr. Neurovasc. Res., 2009, 6(1), 70-81.
40. Beedanagari, S.R.; Bebenek, I.; Bui, P.; Hankinson, O. Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes. Toxicol. Sci. J. Soc. Toxicol., 2009, 110(1), 61-67.
41. Shimada, T.; Fujii-Kuriyama, Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci., 2004, 95(1), 1-6.
42. Denison, M.S.; Whitlock, J.P., Jr. Xenobiotic-inducible transcription of cytochrome P450 genes. J. Biol. Chem., 1995, 270(31), 18175-18178.
43. Bishayee, A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res. (Phila), 2009, 2(5), 409-418.
44. Hussain, A.R.; Uddin, S.; Bu, R.; Khan, O.S.; Ahmed, S.O.; Ahmed, M.; Al-Kuraya, K.S. Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell lines. PloS One, 2011, 6(9), e24703.
45. Ge, J.; Liu, Y.; Li, Q.; Guo, X.; Gu, L.; Ma, Z.G.; Zhu, Y.P. Resveratrol induces apoptosis and autophagy in T-cell acute lymphoblastic leukemia cells by inhibiting Akt/mTOR and activating p38-MAPK. Biomed. Environ. Sci., 2013, 26(11), 902-911.
46. Wu, Z.; Liu, B.; E, C.; Liu, J.; Zhang, Q.; Chen, N.; Chen, R.; Zhu, R. Resveratrol inhibits the proliferation of human melanoma cells by inducing G1/S cell cycle arrest and apoptosis. Mol. Med. Rep., 2014.
47. Ferruelo, A.; Romero, I.; Cabrera, P.M.; Arance, I.; Andres, G.; Angulo, J.C. Effects of resveratrol and other wine polyphenols on the proliferation, apoptosis and androgen receptor expression in LNCaP cells. Actas urolog. Espanol., 2014, 38(6), 397-404.
48. Juan, M.E.; Alfaras, I.; Planas, J.M. Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol. Res., 2012, 65(6), 584-591.
49. Qin, Y.; Ma, Z.; Dang, X.; Li, W.; Ma, Q. Effect of resveratrol on proliferation and apoptosis of human pancreatic cancer MIA PaCa-2 cells may involve inhibition of the Hedgehog signaling pathway. Mol. Med. Rep., 2014, 10(5), 2563-2567.
50. Yang, Q.; Wang, B.; Zang, W.; Wang, X.; Liu, Z.; Li, W.; Jia, J. Resveratrol inhibits the growth of gastric cancer by inducing G1 phase arrest and senescence in a Sirt1-dependent manner. PloS One, 2013, 8(11), e70627.
51. Stakleff, K.S.; Sloan, T.; Blanco, D.; Marcanthony, S.; Booth, T.D.; Bishayee, A. Resveratrol exerts differential effects in vitro and in vivo against ovarian cancer cells. APJCP, 2012, 13(4), 1333-1340.
52. Sexton, E.; Van Themsche, C.; LeBlanc, K.; Parent, S.; Lemoine, P.; Asselin, E. Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol. cancer, 2006, 5, 45.
53. Zhang, H.; Yang, R. Resveratrol inhibits VEGF gene expression and proliferation of hepatocarcinoma cells. Hepatogastroenterology, 2014, 61(130), 410-412.
54. Le Corre, L.; Chalabi, N.; Delort, L.; Bignon, Y.J.; Bernard-Gallon, D.J., Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol. Nutri. Food Res., 2005, 49(5), 462-471.
55. Pozo-Guisado, E.; Lorenzo-Benayas, M.J.; Fernandez-Salguero, P.M. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Intl J. Cancer, 2004, 109(2), 167-173.
56. Pozo-Guisado, E.; Alvarez-Barrientos, A.; Mulero-Navarro, S.; Santiago-Josefat, B.; Fernandez-Salguero, P.M. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem. Pharmacol., 2002, 64(9), 1375-1386.
57. Clement, M.V.; Hirpara, J.L.; Chawdhury, S.H.; Pervaiz, S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood, 1998, 92(3), 996-1002.
58. Nakagawa, H.; Kiyozuka, Y.; Uemura, Y.; Senzaki, H.; Shikata, N.; Hioki, K.; Tsubura, A. Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator. J. Cancer Res. Clin. Oncol., 2001, 127(4), 258-264.
59. Mgbonyebi, O.P.; Russo, J.; Russo, I.H. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Intl J. Oncol., 1998, 12(4), 865-869.
60. Gehm, B.D.; McAndrews, J.M.; Chien, P.Y.; Jameson, J.L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Nat. Acad. Sci. U.S.A., 1997, 94(25), 14138-14143.
61. Basly, J.P.; Marre-Fournier, F.; Le Bail, J.C.; Habrioux, G.; Chulia, A.J. Estrogenic/antiestrogenic and scavenging properties of (E)-and (Z)-resveratrol. Life Sci., 2000, 66(9), 769-777.
62. Athar, M.; Back, J.H.; Kopelovich, L.; Bickers, D.R.; Kim, A.L. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch. Biochem. Biophy., 2009, 486(2), 95-102.
63. Laux, M.T.; Aregullin, M.; Berry, J.P.; Flanders, J.A.; Rodriguez, E. Identification of a p53-dependent pathway in the induction of apoptosis of human breast cancer cells by the natural product, resveratrol. J. Altern. Complement. Med., 2004, 10(2), 235-239.
64. Khan, A.; Aljarbou, A.N.; Aldebasi, Y.H.; Faisal, S.M.; Khan, M.A. Resveratrol suppresses the proliferation of breast cancer cells by inhibiting fatty acid synthase signaling pathway. Cancer Epidemiol., 2014, 38(6), 765-772.
65. Liu, B.; Zhou, Z.; Zhou, W.; Liu, J.; Zhang, Q.; Xia, J.; Chen, N.; Li, M.; Zhu, R. Resveratrol inhibits proliferation in human colorectal carcinoma cells by inducing G1/Sphase cell cycle arrest and apoptosis through caspase/cyclinCDK pathways. Mol. Med. Rep., 2014, 10(4), 1697-1702.
66. Lanzilli, G.; Fuggetta, M.P.; Tricarico, M.; Cottarelli, A.; Serafino, A.; Falchetti, R.; Ravagnan, G.; Turriziani, M.; Adamo, R.; Franzese, O.; Bonmassar, E. Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. Intl J. Oncol., 2006, 28(3), 641-648.
67. Schneider, Y.; Vincent, F.; Duranton, B.; Badolo, L.; Gosse, F.; Bergmann, C.; Seiler, N.; Raul, F. Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett., 2000, 158(1), 85-91.
68. Ferraz da Costa, D.C.; Casanova, F.A.; Quarti, J.; Malheiros, M.S.; Sanches, D.; Dos Santos, P.S.; Fialho, E.; Silva, J.L. Transient transfection of a wild-type p53 gene triggers resveratrol-induced apoptosis in cancer cells. PloS One, 2012, 7(11), e48746.
69. Pozo-Guisado, E.; Merino, J.M.; Mulero-Navarro, S.; Lorenzo-Benayas, M.J.; Centeno, F.; Alvarez-Barrientos, A.; Fernandez-Salguero, P.M. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Intl J. Cancer, 2005, 115(1), 74-84.
70. Walle, T. Bioavailability of resveratrol. Ann. New York Acad. Sci., 2011, 1215, 9-15.
71. Walle, T.; Hsieh, F.; DeLegge, M.H.; Oatis, J.E., Jr.; Walle, U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabol. Disposit., 2004, 32(12), 1377-1382.
72. Carter, L.G.; D'Orazio, J.A.; Pearson, K.J. Resveratrol and cancer: focus on in vivo evidence. Endocrine-related Cancer, 2014, 21(3), R209-225.
73. Boocock, D.J.; Faust, G.E.; Patel, K.R.; Schinas, A.M.; Brown, V.A.; Ducharme, M.P.; Booth, T.D.; Crowell, J.A.; Perloff, M.; Gescher, A.J.; Steward, W.P.; Brenner, D.E. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer epidemiol. Biomark. Preven.: A publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2007, 16(6), 1246-1252.
74. Bhat, K.P.; Lantvit, D.; Christov, K.; Mehta, R.G.; Moon, R.C.; Pezzuto, J.M. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res., 2001, 61(20), 7456-7463.
75. Lu, R.; Serrero, G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J. Cell. Physiol., 1999, 179(3), 297-304.
76. Ruotolo, R.; Calani, L.; Fietta, E.; Brighenti, F.; Crozier, A.; Meda, C.; Maggi, A.; Ottonello, S.; Del Rio, D. Anti-estrogenic activity of a human resveratrol metabolite. Nutrit. Metabol. Cardiovasc. Dis., 2013, 23(11), 1086-1092.
77. Bowers, J.L.; Tyulmenkov, V.V.; Jernigan, S.C.; Klinge, C.M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology, 2000, 141(10), 3657-3667.
78. Mueller, S.O.; Simon, S.; Chae, K.; Metzler, M.; Korach, K.S. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. J. Soc. Toxicol., 2004, 80(1), 14-25.
79. Serrero, G.; Lu, R. Effect of resveratrol on the expression of autocrine growth modulators in human breast cancer cells. Antioxid. Redox Signal., 2001, 3(6), 969-979.
80. Turner, R.T.; Evans, G.L.; Zhang, M.; Maran, A.; Sibonga, J.D. Is resveratrol an estrogen agonist in growing rats? Endocrinology, 1999, 140(1), 50-54.
81. Garvin, S.; Ollinger, K.; Dabrosin, C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett., 2006, 231(1), 113-122.
82. Banerjee, S.; Bueso-Ramos, C.; Aggarwal, B.B. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res., 2002, 62(17), 4945-4954.
83. Whitsett, T.; Carpenter, M.; Lamartiniere, C.A. Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J. Carcinogenes., 2006, 5, 15.
84. Chatterjee, M.; Das, S.; Janarthan, M.; Ramachandran, H.K. Role of 5-lipoxygenase in resveratrol mediated suppression of 7,12-dimethylbenz(alpha)anthracene-induced mammary carcinogenesis in rats. Eur. J. Pharmacol., 2011, 668(1-2), 99-106.
85. Provinciali, M.; Re, F.; Donnini, A.; Orlando, F.; Bartozzi, B.; Di Stasio, G.; Smorlesi, A. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Intl J. Cancer, 2005, 115(1), 36-45.
86. Fu, Y.; Chang, H.; Peng, X.; Bai, Q.; Yi, L.; Zhou, Y.; Zhu, J.; Mi, M. Resveratrol inhibits breast cancer stem-like cells and induces autophagy via suppressing Wnt/beta-catenin signaling pathway. PloS One, 2014, 9(7), e102535.
87. Sato, M.; Pei, R.J.; Yuri, T.; Danbara, N.; Nakane, Y.; Tsubura, A. Prepubertal resveratrol exposure accelerates N-methyl-Nnitrosourea-induced mammary carcinoma in female Sprague-Dawley rats. Cancer Lett., 2003, 202(2), 137-145.
88. Bove, K.; Lincoln, D.W.; Tsan, M.F. Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem. Biophy. Res. Commun., 2002, 291(4), 1001-1005.
89. Castillo-Pichardo, L.; Cubano, L.A.; Dharmawardhane, S. Dietary grape polyphenol resveratrol increases mammary tumor growth and metastasis in immunocompromised mice. BMC Complement. Altern. Med., 2013, 13, 6.
90. Juan, M.E.; Vinardell, M.P.; Planas, J.M. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J. Nutri., 2002, 132(2), 257-260.
91. Crowell, J.A.; Korytko, P.J.; Morrissey, R.L.; Booth, T.D.; Levine, B.S. Resveratrol-associated renal toxicity. Toxicol. Sci., 2004, 82(2), 614-619.
92. Fulda, S. Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov. Today, 2010, 15(17-18), 757-765.
93. Ma, Z.; Molavi, O.; Haddadi, A.; Lai, R.; Gossage, R.A.; Lavasanifar, A. Resveratrol analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol. Cancer chemother. Pharmacol., 2008, 63(1), 27-35.
94. Pan, M.H.; Lin, C.L.; Tsai, J.H.; Ho, C.T.; Chen, W.J. 3,5,3',4',5'-pentamethoxystilbene (MR-5), a synthetically methoxylated analogue of resveratrol, inhibits growth and induces G1 cell cycle arrest of human breast carcinoma MCF-7 cells. J. Agri. Food Chem., 2010, 58(1), 226-234.
95. Kapetanovic, I.M.; Muzzio, M.; Huang, Z.; Thompson, T.N.; McCormick, D.L. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother. Pharmacol., 2011, 68(3), 593-601.
96. Alosi, J.A.; McDonald, D.E.; Schneider, J.S.; Privette, A.R.; McFadden, D.W. Pterostilbene inhibits breast cancer in vitro through mitochondrial depolarization and induction of caspasedependent apoptosis. J. Surg. Res., 2010, 161(2), 195-201.
97. Mannal, P.; McDonald, D.; McFadden, D. Pterostilbene and tamoxifen show an additive effect against breast cancer in vitro. Am. J. Surg., 2010, 200(5), 577-580.
98. Wang, Y.; Ding, L.; Wang, X.; Zhang, J.; Han, W.; Feng, L.; Sun, J.; Jin, H.; Wang, X.J. Pterostilbene simultaneously induces apoptosis, cell cycle arrest and cyto-protective autophagy in breast cancer cells. Am. J. Translat. Res., 2012, 4(1), 44-51.
99. Mak, K.K.; Wu, A.T.; Lee, W.H.; Chang, T.C.; Chiou, J.F.; Wang, L.S.; Wu, C.H.; Huang, C.Y.; Shieh, Y.S.; Chao, T.Y.; Ho, C.T.; Yen, G.C.; Yeh, C.T. Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NFkappaB/ microRNA 448 circuit. Mol. Nutri. Food Res., 2013, 57(7), 1123-1134.
100. Hagiwara, K.; Kosaka, N.; Yoshioka, Y.; Takahashi, R.U.; Takeshita, F.; Ochiya, T. Stilbene derivatives promote Ago2-dependent tumour-suppressive microRNA activity. Scientific Rep., 2012, 2, 314.
101. Nikhil, K.; Sharan, S.; Singh, A.K.; Chakraborty, A.; Roy, P. Anticancer activities of pterostilbene-isothiocyanate conjugate in breast cancer cells: involvement of PPARgamma. PloS One, 2014, 9(8), e104592.
102. Kim, K.Y.; Kim, S.S.; Cheon, H.G. Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochem. Pharmacol., 2006, 72(5), 530-540.
103. Tsai, J.H.; Hsu, L.S.; Lin, C.L.; Hong, H.M.; Pan, M.H.; Way, T.D.; Chen, W.J. 3,5,4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/beta-catenin signaling cascades and reversal of epithelial-mesenchymal transition. Toxicol. App. Pharmacol., 2013, 272(3), 746-756.
104. Hsieh, T.C.; Wong, C.; John Bennett, D.; Wu, J.M. Regulation of p53 and cell proliferation by resveratrol and its derivatives in breast cancer cells: an in silico and biochemical approach targeting integrin alphavbeta3. Intl. J. Cancer, 2011, 129(11), 2732-2743.
105. Sale, S.; Verschoyle, R.D.; Boocock, D.; Jones, D.J.; Wilsher, N.; Ruparelia, K.C.; Potter, G.A.; Farmer, P.B.; Steward, W.P.; Gescher, A.J. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene. Br. J. Cancer, 2004, 90(3), 736-744.
106. Androutsopoulos, V.P.; Ruparelia, K.C.; Papakyriakou, A.; Filippakis, H.; Tsatsakis, A.M.; Spandidos, D.A. Anticancer effects of the metabolic products of the resveratrol analogue, DMU-212: structural requirements for potency. Eur. J. Med. Chem., 2011, 46(6), 2586-2595.
107. Ovesna, Z.; Horvathova-Kozics, K. Structure-activity relationship of trans-resveratrol and its analogues. Neoplasma, 2005, 52(6), 450-455.
108. Stivala, L.A.; Savio, M.; Carafoli, F.; Perucca, P.; Bianchi, L.; Maga, G.; Forti, L.; Pagnoni, U.M.; Albini, A.; Prosperi, E.; Vannini, V. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J. Biol. Chem., 2001, 276(25), 22586-22594.
109. Cai, Y.J.; Fang, J.G.; Ma, L.P.; Yang, L.; Liu, Z.L. Inhibition of free radical-induced peroxidation of rat liver microsomes by resveratrol and its analogues. Biochim. Biophy. Acta, 2003, 1637(1), 31-38.
110. Fang, H.; Tong, W.; Shi, L.M.; Blair, R.; Perkins, R.; Branham, W.; Hass, B.S.; Xie, Q.; Dial, S.L.; Moland, C.L.; Sheehan, D.M. Structure-activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. Chem. Res. Toxicol., 2001, 14(3), 280-294.
111. Savio, M.; Coppa, T.; Bianchi, L.; Vannini, V.; Maga, G.; Forti, L.; Cazzalini, O.; Lazze, M.C.; Perucca, P.; Prosperi, E.; Stivala, L.A. The resveratrol analogue 4,4'-dihydroxy-trans-stilbene inhibits cell proliferation with higher efficiency but different mechanism from resveratrol. Intl. J. Biochem. Cell Biol., 2009, 41(12), 2493-2502.
112. Maccario, C.; Savio, M.; Ferraro, D.; Bianchi, L.; Pizzala, R.; Pretali, L.; Forti, L.; Stivala, L.A. The resveratrol analog 4,4'-dihydroxy-trans-stilbene suppresses transformation in normal mouse fibroblasts and inhibits proliferation and invasion of human breast cancer cells. Carcinogenesis, 2012, 33(11), 2172-2180.
113. Murias, M.; Luczak, M.W.; Niepsuj, A.; Krajka-Kuzniak, V.; Zielinska-Przyjemska, M.; Jagodzinski, P.P.; Jager, W.; Szekeres, T.; Jodynis-Liebert, J. Cytotoxic activity of 3,3',4,4',5,5'-hexahydroxystilbene against breast cancer cells is mediated by induction of p53 and downregulation of mitochondrial superoxide dismutase. Toxicol in vitro, 2008, 22(5), 1361-1370.
114. Sun, B.; Hoshino, J.; Jermihov, K.; Marler, L.; Pezzuto, J.M.; Mesecar, A.D.; Cushman, M. Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg. Med. Chem., 2010, 18(14), 5352-5366.
115. Mayhoub, A.S.; Marler, L.; Kondratyuk, T.P.; Park, E.J.; Pezzuto, J.M.; Cushman, M. Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol. Bioorg. Med. Chem., 2012, 20(7), 2427-2434.
116. Sala, M.; Chimento, A.; Saturnino, C.; Gomez-Monterrey, I.M.; Musella, S.; Bertamino, A.; Milite, C.; Sinicropi, M.S.; Caruso, A.; Sirianni, R.; Tortorella, P.; Novellino, E.; Campiglia, P.; Pezzi, V. Synthesis and cytotoxic activity evaluation of 2,3-thiazolidin-4-one derivatives on human breast cancer cell lines. Bioorg. Med. Chem. Lett., 2013, 23(17), 4990-4995.
117. Lappano, R.; De Marco, P.; De Francesco, E.M.; Chimento, A.; Pezzi, V.; Maggiolini, M. Cross-talk between GPER and growth factor signaling. J. Ster. Biochem. Mol. Biol., 2013, 137, 50-56.
118. Chimento, A.; Casaburi, I.; Rosano, C.; Avena, P.; De Luca, A.; Campana, C.; Martire, E.; Santolla, M.F.; Maggiolini, M.; Pezzi, V.; Sirianni, R. Oleuropein and hydroxytyrosol activate GPER/ GPR30-dependent pathways leading to apoptosis of ER-negative SKBR3 breast cancer cells. Mol. Nutri. Food Res., 2014, 58(3), 478-489.
119. Chimento, A.; Sala, M.; Gomez-Monterrey, I.M.; Musella, S.; Bertamino, A.; Caruso, A.; Sinicropi, M.S.; Sirianni, R.; Puoci, F.; Parisi, O.I.; Campana, C.; Martire, E.; Novellino, E.; Saturnino, C.; Campiglia, P.; Pezzi, V. Biological activity of 3-chloro-azetidin-2-one derivatives having interesting antiproliferative activity on human breast cancer cell lines. Bioorg. Med. Chem. Lett., 2013, 23(23), 6401-6405.
120. Kim, H.J.; Yang, K.M.; Park, Y.S.; Choi, Y.J.; Yun, J.H.; Son, C.H.; Suh, H.S.; Jeong, M.H.; Jo, W.S. The novel resveratrol analogue HS-1793 induces apoptosis via the mitochondrial pathway in murine breast cancer cells. Intl. J. Oncol., 2012, 41(5), 1628-1634.
121. Kim, J.A.; Kim, D.H.; Hossain, M.A.; Kim, M.Y.; Sung, B.; Yoon, J.H.; Suh, H.; Jeong, T.C.; Chung, H.Y.; Kim, N.D. HS-1793, a resveratrol analogue, induces cell cycle arrest and apoptotic cell death in human breast cancer cells. Intl. J. Oncol., 2014, 44(2), 473-480.